Pegzilarginase

Pegzilarginase, sold under the brand name Loargys, is a medication used for the treatment of hyperargininemia.
The most common side effects include allergic reactions.
Pegzilarginase was approved for medical use in the European Union in December 2023.

Medical uses

Pegzilarginase is indicated for the treatment of arginase 1 deficiency, also known as hyperargininemia.

Society and culture

Legal status

In October 2023, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Loargys, intended for the treatment of hyperargininemia. The applicant for this medicinal product is Immedica Pharma AB. Pegzilarginase was approved for medical use in the European Union in December 2023.

Brand names

Pegzilarginase is the international nonproprietary name.
Pegzilarginase is sold under the brand name Loargys.